FDA approves weight-loss drug to treat sleep apnea

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans.

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) and obesity.

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” Dr. Sally Seymour, director of the Division of Pulmonology, Allergy and Critical Care in the FDA’s Center for Drug Evaluation and Research, said in a statement. “This is a major step forward for patients with obstructive sleep apnea.”

OSA is a sleep-related breathing disorder among individuals who briefly stop breathing during sleep. There are many symptoms of OSA, including disrupted sleep, fatigue, snoring and excessive daytime sleeplessness.

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in adults with obesity,” the president of Lilly Cardiometabolic Health and Lilly USA Patrik Jonsson said in a statement. "Nearly half of clinical trial patients saw such improvements that they no longer had symptoms associated with OSA, marking a critical step forward in reducing the burden of this disease and its interconnected health challenges."

OSA afflicts over 25 million adults in the U.S., according to the National Healthy Sleep Awareness Project.

FDA said that Zepbound works by activating receptors of hormones to cut down on the food intake and appetite of the patients. Some studies have shown that the approved drug improves OSA with weight reduction.

The federal regulator said that Zepbound’s approval came following two placebo-controlled, randomized studies among 469 adults who did not have type 2 diabetes.

Topics

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.
CNBC - 1d
FDA approves weight loss drug Zepbound for sleep apnea

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.
NBC News - 1d
Eli Lilly given US approval to treat sleep disorder with weight-loss drug

Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Financial Times - 1d
F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

Zepbound is the first prescription drug approved specifically to treat the common condition.
The New York Times - 1d
FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage

The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
CNBC - 2d
Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

In Michigan, the state’s largest insurer has tightened restrictions around medications like Wegovy. Patients are panicking.
The New York Times - 3d
FDA warns companies over unapproved weight loss drug sales

The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, ...
The Hill - 3d
What other conditions could weight-loss drugs treat?

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
Financial Times - Dec. 12
Millions will have to wait up to 12 years for NHS weight-loss drug

Fears that giving 3.4 million people immediate access to new weight-loss drug could overwhelm NHS.
BBC News - Dec. 5